Brief: Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
26/02/2026 21:05
Feb 26 (Reuters) - Neurogene Inc NGNE.O: NEUROGENE ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR NGN-401 GENE THERAPY FOR RETT SYNDROME NEUROGENE INC - DOSING IN EMBOLDEN TRIAL TO COMPLETE BY Q2 2026 NEUROGENE INC - ADDITIONAL PHASE 1/2 DATA TO BE PRESENTED MID-2026 Source text: ID:nBw61qrxga Further company coverage: NGNE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurogene
See all newsBrief: Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary
Neurogene Q2 adjusted loss per share misses estimates on employee costs
Neurogene Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kroger, Meta, Sable